Hypermethylation of tachykinin-1 is a potential biomarker in human esophageal cancer

Zhe Jin, Alexandru Olaru, Jian Yang, Fumiaki Sato, Yulan Cheng, Takatsugu Kan, Yuriko Mori, Carmit Mantzur, Bogdan Paun, James Hamilton, Tetsuo Ito, Suna Wang, Stefan David, Rachana Agarwal, David G. Beer, John M. Abraham, Stephen Meltzer

Research output: Contribution to journalArticle

Abstract

Purpose: Our aim was to investigate whether and at what stage hypermethylation of the tachykinin-1 (TAC1) gene is associated with human esophageal neoplastic transformation. Experimental Design: TAC1 promoter hypermethylation was examined by real-time methylation-specific PCR in 258 human esophageal specimens and 126 plasma samples from patients or tissues at various stages of neoplastic evolution. Results: TAC1 hypermethylation in tissue samples showed highly discriminative receiver-operator characteristic curve profiles, clearly distinguishing esophageal squamous cell carcinoma (ESCC) and esophageal adenocarcinoma (EAC) from normal esophagus (P <0.0001). Both frequencies and normalized methylation values of TAC1 tissue methylation were significantly higher in Barrett's metaplasia (BE), dysplastic Barrett's esophagus, EAC, and ESCC than in normal esophagus (P <0.01). The frequency of TAC1 hypermethylation increased dramatically and early during neoplastic progression, from 7.5% in normal esophagus to 55.6% in BE from patients with Barrett's metaplasia alone, 57.5% in dysplastic Barrett's esophagus, and 61.2% in EAC. There was a significant relationship between TAC1 hypermethylation and BE segment length, a known clinical risk factor for neoplastic progression. Twelve (50%) of 24 ESCC exhibited TAC1 hypermethylation. Overall patient survival correlated significantly with TAC1 methylation status in ESCC patients (mean survival, 22 versus 110 months; P = 0.0102, log-rank test), but not in EAC patients. Both mean normalized methylation values and frequency of TAC1 hypermethylation in plasma samples were significantly higher in EAC patients than in control subjects. Treatment of KYSE220 ESCC and BIC EAC cells with 5-aza-2′-deoxycytidine reduced TAC1 methylation and increased TAC1 mRNA expression. Conclusions: TAC1 promoter hypermethylation is a common event in bothmajor histologic types of human esophageal carcinoma, occurs early, correlates with other progression risk factors in esophageal adenocarcinogenesis, and is a tissue biomarker of a poor prognosis in ESCC. Circulating methylated TAC1 promoter DNA also offers potential as a biomarker for the diagnosis of EAC.

Original languageEnglish (US)
Pages (from-to)6293-6300
Number of pages8
JournalClinical Cancer Research
Volume13
Issue number21
DOIs
StatePublished - Nov 1 2007

Fingerprint

Tachykinins
Esophageal Neoplasms
Biomarkers
Barrett Esophagus
Methylation
Adenocarcinoma
decitabine
imidazole mustard
Esophagus
Survival
Esophageal Squamous Cell Carcinoma

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Hypermethylation of tachykinin-1 is a potential biomarker in human esophageal cancer. / Jin, Zhe; Olaru, Alexandru; Yang, Jian; Sato, Fumiaki; Cheng, Yulan; Kan, Takatsugu; Mori, Yuriko; Mantzur, Carmit; Paun, Bogdan; Hamilton, James; Ito, Tetsuo; Wang, Suna; David, Stefan; Agarwal, Rachana; Beer, David G.; Abraham, John M.; Meltzer, Stephen.

In: Clinical Cancer Research, Vol. 13, No. 21, 01.11.2007, p. 6293-6300.

Research output: Contribution to journalArticle

Jin, Z, Olaru, A, Yang, J, Sato, F, Cheng, Y, Kan, T, Mori, Y, Mantzur, C, Paun, B, Hamilton, J, Ito, T, Wang, S, David, S, Agarwal, R, Beer, DG, Abraham, JM & Meltzer, S 2007, 'Hypermethylation of tachykinin-1 is a potential biomarker in human esophageal cancer', Clinical Cancer Research, vol. 13, no. 21, pp. 6293-6300. https://doi.org/10.1158/1078-0432.CCR-07-0818
Jin, Zhe ; Olaru, Alexandru ; Yang, Jian ; Sato, Fumiaki ; Cheng, Yulan ; Kan, Takatsugu ; Mori, Yuriko ; Mantzur, Carmit ; Paun, Bogdan ; Hamilton, James ; Ito, Tetsuo ; Wang, Suna ; David, Stefan ; Agarwal, Rachana ; Beer, David G. ; Abraham, John M. ; Meltzer, Stephen. / Hypermethylation of tachykinin-1 is a potential biomarker in human esophageal cancer. In: Clinical Cancer Research. 2007 ; Vol. 13, No. 21. pp. 6293-6300.
@article{589f4849400f4449904168ae7487ee10,
title = "Hypermethylation of tachykinin-1 is a potential biomarker in human esophageal cancer",
abstract = "Purpose: Our aim was to investigate whether and at what stage hypermethylation of the tachykinin-1 (TAC1) gene is associated with human esophageal neoplastic transformation. Experimental Design: TAC1 promoter hypermethylation was examined by real-time methylation-specific PCR in 258 human esophageal specimens and 126 plasma samples from patients or tissues at various stages of neoplastic evolution. Results: TAC1 hypermethylation in tissue samples showed highly discriminative receiver-operator characteristic curve profiles, clearly distinguishing esophageal squamous cell carcinoma (ESCC) and esophageal adenocarcinoma (EAC) from normal esophagus (P <0.0001). Both frequencies and normalized methylation values of TAC1 tissue methylation were significantly higher in Barrett's metaplasia (BE), dysplastic Barrett's esophagus, EAC, and ESCC than in normal esophagus (P <0.01). The frequency of TAC1 hypermethylation increased dramatically and early during neoplastic progression, from 7.5{\%} in normal esophagus to 55.6{\%} in BE from patients with Barrett's metaplasia alone, 57.5{\%} in dysplastic Barrett's esophagus, and 61.2{\%} in EAC. There was a significant relationship between TAC1 hypermethylation and BE segment length, a known clinical risk factor for neoplastic progression. Twelve (50{\%}) of 24 ESCC exhibited TAC1 hypermethylation. Overall patient survival correlated significantly with TAC1 methylation status in ESCC patients (mean survival, 22 versus 110 months; P = 0.0102, log-rank test), but not in EAC patients. Both mean normalized methylation values and frequency of TAC1 hypermethylation in plasma samples were significantly higher in EAC patients than in control subjects. Treatment of KYSE220 ESCC and BIC EAC cells with 5-aza-2′-deoxycytidine reduced TAC1 methylation and increased TAC1 mRNA expression. Conclusions: TAC1 promoter hypermethylation is a common event in bothmajor histologic types of human esophageal carcinoma, occurs early, correlates with other progression risk factors in esophageal adenocarcinogenesis, and is a tissue biomarker of a poor prognosis in ESCC. Circulating methylated TAC1 promoter DNA also offers potential as a biomarker for the diagnosis of EAC.",
author = "Zhe Jin and Alexandru Olaru and Jian Yang and Fumiaki Sato and Yulan Cheng and Takatsugu Kan and Yuriko Mori and Carmit Mantzur and Bogdan Paun and James Hamilton and Tetsuo Ito and Suna Wang and Stefan David and Rachana Agarwal and Beer, {David G.} and Abraham, {John M.} and Stephen Meltzer",
year = "2007",
month = "11",
day = "1",
doi = "10.1158/1078-0432.CCR-07-0818",
language = "English (US)",
volume = "13",
pages = "6293--6300",
journal = "Clinical Cancer Research",
issn = "1078-0432",
publisher = "American Association for Cancer Research Inc.",
number = "21",

}

TY - JOUR

T1 - Hypermethylation of tachykinin-1 is a potential biomarker in human esophageal cancer

AU - Jin, Zhe

AU - Olaru, Alexandru

AU - Yang, Jian

AU - Sato, Fumiaki

AU - Cheng, Yulan

AU - Kan, Takatsugu

AU - Mori, Yuriko

AU - Mantzur, Carmit

AU - Paun, Bogdan

AU - Hamilton, James

AU - Ito, Tetsuo

AU - Wang, Suna

AU - David, Stefan

AU - Agarwal, Rachana

AU - Beer, David G.

AU - Abraham, John M.

AU - Meltzer, Stephen

PY - 2007/11/1

Y1 - 2007/11/1

N2 - Purpose: Our aim was to investigate whether and at what stage hypermethylation of the tachykinin-1 (TAC1) gene is associated with human esophageal neoplastic transformation. Experimental Design: TAC1 promoter hypermethylation was examined by real-time methylation-specific PCR in 258 human esophageal specimens and 126 plasma samples from patients or tissues at various stages of neoplastic evolution. Results: TAC1 hypermethylation in tissue samples showed highly discriminative receiver-operator characteristic curve profiles, clearly distinguishing esophageal squamous cell carcinoma (ESCC) and esophageal adenocarcinoma (EAC) from normal esophagus (P <0.0001). Both frequencies and normalized methylation values of TAC1 tissue methylation were significantly higher in Barrett's metaplasia (BE), dysplastic Barrett's esophagus, EAC, and ESCC than in normal esophagus (P <0.01). The frequency of TAC1 hypermethylation increased dramatically and early during neoplastic progression, from 7.5% in normal esophagus to 55.6% in BE from patients with Barrett's metaplasia alone, 57.5% in dysplastic Barrett's esophagus, and 61.2% in EAC. There was a significant relationship between TAC1 hypermethylation and BE segment length, a known clinical risk factor for neoplastic progression. Twelve (50%) of 24 ESCC exhibited TAC1 hypermethylation. Overall patient survival correlated significantly with TAC1 methylation status in ESCC patients (mean survival, 22 versus 110 months; P = 0.0102, log-rank test), but not in EAC patients. Both mean normalized methylation values and frequency of TAC1 hypermethylation in plasma samples were significantly higher in EAC patients than in control subjects. Treatment of KYSE220 ESCC and BIC EAC cells with 5-aza-2′-deoxycytidine reduced TAC1 methylation and increased TAC1 mRNA expression. Conclusions: TAC1 promoter hypermethylation is a common event in bothmajor histologic types of human esophageal carcinoma, occurs early, correlates with other progression risk factors in esophageal adenocarcinogenesis, and is a tissue biomarker of a poor prognosis in ESCC. Circulating methylated TAC1 promoter DNA also offers potential as a biomarker for the diagnosis of EAC.

AB - Purpose: Our aim was to investigate whether and at what stage hypermethylation of the tachykinin-1 (TAC1) gene is associated with human esophageal neoplastic transformation. Experimental Design: TAC1 promoter hypermethylation was examined by real-time methylation-specific PCR in 258 human esophageal specimens and 126 plasma samples from patients or tissues at various stages of neoplastic evolution. Results: TAC1 hypermethylation in tissue samples showed highly discriminative receiver-operator characteristic curve profiles, clearly distinguishing esophageal squamous cell carcinoma (ESCC) and esophageal adenocarcinoma (EAC) from normal esophagus (P <0.0001). Both frequencies and normalized methylation values of TAC1 tissue methylation were significantly higher in Barrett's metaplasia (BE), dysplastic Barrett's esophagus, EAC, and ESCC than in normal esophagus (P <0.01). The frequency of TAC1 hypermethylation increased dramatically and early during neoplastic progression, from 7.5% in normal esophagus to 55.6% in BE from patients with Barrett's metaplasia alone, 57.5% in dysplastic Barrett's esophagus, and 61.2% in EAC. There was a significant relationship between TAC1 hypermethylation and BE segment length, a known clinical risk factor for neoplastic progression. Twelve (50%) of 24 ESCC exhibited TAC1 hypermethylation. Overall patient survival correlated significantly with TAC1 methylation status in ESCC patients (mean survival, 22 versus 110 months; P = 0.0102, log-rank test), but not in EAC patients. Both mean normalized methylation values and frequency of TAC1 hypermethylation in plasma samples were significantly higher in EAC patients than in control subjects. Treatment of KYSE220 ESCC and BIC EAC cells with 5-aza-2′-deoxycytidine reduced TAC1 methylation and increased TAC1 mRNA expression. Conclusions: TAC1 promoter hypermethylation is a common event in bothmajor histologic types of human esophageal carcinoma, occurs early, correlates with other progression risk factors in esophageal adenocarcinogenesis, and is a tissue biomarker of a poor prognosis in ESCC. Circulating methylated TAC1 promoter DNA also offers potential as a biomarker for the diagnosis of EAC.

UR - http://www.scopus.com/inward/record.url?scp=35948943898&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=35948943898&partnerID=8YFLogxK

U2 - 10.1158/1078-0432.CCR-07-0818

DO - 10.1158/1078-0432.CCR-07-0818

M3 - Article

C2 - 17975140

AN - SCOPUS:35948943898

VL - 13

SP - 6293

EP - 6300

JO - Clinical Cancer Research

JF - Clinical Cancer Research

SN - 1078-0432

IS - 21

ER -